Exhibit 99.1 Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights – Phase 2 proof-of-concept trials remain on track: Topline data expected from ALTO-203 in MDD in the second quarter of 2025 followed by ALTO-101 in schizophrenia in the second half of 2025 – – Late-stage programs advancing: Topline data expected from the Phase 2b trial of ALTO-300 in MDD in mid- 2026 followed by the Phase 2b trial of ALTO-100 in bipolar depression in the second half of 2026 – – New dat ...